Boehringer Ingelheim Gets €540M upfront for the next Potential Antibody Blockbuster

09/03/2016 - 3 minutes

Boehringer Ingelheim (Germany) has entered a new collaboration with AbbVie (US) to develop two new candidates for immune diseases, including psoriasis and Crohn’s disease.

boehringer_ingelheim_abbvie_immune_psoriasis_crohn's_asthma_psoriatic_arthritisTherapies for immune diseases continue to attract Pharma’s attention (and money). This time, two of 25 leading Big Pharma worldwide, AbbVie and Boehringer Ingelheim, have partnered to develop 2 different immunological candidates.

One of the candidates is BI 655064, an antagonistic anti-CD40 antibody in phase I development. Tackling the CD40-CD40L pathway (involved in modulating immune response), it could potentially be used to treat a range of immune diseases like lupus nephritis, Crohn’s disease and ulcerative colitis.

But the forefront candidate is BI 655066, which is already in phase III trials. The drug is an anti-IL-23 antibody, which aims to block Interleukin-23 (signalling protein) involved in skin inflammation.

A drug with the same mechanism of action, ustekinumab, is already on the market. It is commercialized as Stelara by Jansen (J&J‘s pharmaceutical subsidiary,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member